{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:24:56Z","timestamp":1787793896875,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of the work was to evaluate and compare the effectiveness and safety of intradermal tranexamic acid (TXA) versus intradermal platelet-rich plasma (PRP) in the treatment of various types of melasma. The current split-face prospective study included 40 cases with melasma. Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4\u00a0mg\/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side. In both sides, a total of three sessions of treatment were provided, once every 4\u00a0weeks. Digital photographs were taken before each treatment session and 3\u00a0months after the last session. The modified melasma area severity index (mMASI) grading system and dermoscopy were used to assess the improvement in the condition. The disease severity and percentage of improvement were assessed by mMASI score before and after therapy across both sides of the face. along with determining the degree of satisfaction and side effects among the included cases. The mean mMASI score before therapy in the TXA side was 4.59\u2009\u00b1\u20092.87, while in the PRP side, the mean mMASI score before therapy was 4.72\u2009\u00b1\u20092.72 with no statistically significant difference between the two sides (<jats:italic>p<\/jats:italic>\u2009=\u20090.841). After 3\u00a0months of treatment, the mean mMASI score in the TXA-treated side was 2.49\u2009\u00b1\u20091.58 with a mean percentage of decrease of 45.67\u2009\u00b1\u20098.10%, while in the PRP side, the mean mMASI score after treatment was 2.17\u2009\u00b1\u20091.41 with a mean percentage of decrease of 53.66\u2009\u00b1\u200911.27%. There was a high statistically significant decrease in the mMASI score after treatment on both sides (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); however, the percentage of score reduction in the PRP side compared to the TXA side was statistically higher. Intradermal injection with PRP revealed higher efficacy in the treatment of melasma as compared to TXA injection with no significant difference regarding the associated side effects.<\/jats:p>","DOI":"10.1007\/s00403-023-02580-y","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T13:03:28Z","timestamp":1677675808000},"page":"1763-1770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study"],"prefix":"10.1007","volume":"315","author":[{"given":"Israa Gomaa","family":"Abd Elraouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria Mahran","family":"Obaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Fouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"issue":"6","key":"2580_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/DSS.0000000000001518","volume":"44","author":"HR Bala","year":"2018","unstructured":"Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M (2018) Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg 44(6):814\u2013825","journal-title":"Dermatol Surg"},{"issue":"2","key":"2580_CR2","first-page":"53","volume":"11","author":"R Sarkar","year":"2018","unstructured":"Sarkar R, Ailawadi P, Garg S (2018) Melasma in men: a review of clinical, etiological, and management issues. J Clin Aesthetic Dermatolo 11(2):53","journal-title":"J Clin Aesthetic Dermatolo"},{"key":"2580_CR3","doi-asserted-by":"crossref","unstructured":"Zhang L, Tan W-Q, Fang Q-Q, Zhao W-Y, Zhao Q-M, Gao J, et al. (2018) Tranexamic acid for adults with melasma: a systematic review and meta-analysis. BioMed Research International.","DOI":"10.1155\/2018\/1683414"},{"issue":"6","key":"2580_CR4","first-page":"558","volume":"62","author":"R Sarkar","year":"2017","unstructured":"Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N et al (2017) Medical management of melasma: a review with consensus recommendations by Indian pigmentary expert group. Indian J Dermatol 62(6):558","journal-title":"Indian J Dermatol"},{"key":"2580_CR5","doi-asserted-by":"crossref","unstructured":"Nishida, Takeshi et al. (2017) \u201cTranexamic acid and trauma-induced coagulopathy.\u201d Journal of intensive care 55 (1)","DOI":"10.1186\/s40560-016-0201-0"},{"issue":"2","key":"2580_CR6","first-page":"E7","volume":"101","author":"SL Sheu","year":"2018","unstructured":"Sheu SL (2018) Treatment of melasma using tranexamic acid: what\u2019s known and what\u2019s next. Cutis 101(2):E7\u2013E8","journal-title":"Cutis"},{"issue":"01","key":"2580_CR7","first-page":"192","volume":"7","author":"H-L Wang","year":"2013","unstructured":"Wang H-L, Avila G (2013) Platelet rich plasma: myth or reality? Eur J Dentistry 7(01):192\u2013194","journal-title":"Eur J Dentistry"},{"issue":"4","key":"2580_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0974-2077.150734","volume":"7","author":"R Dhurat","year":"2014","unstructured":"Dhurat R, Sukesh MS (2014) Principles and methods of preparation of platelet-rich plasma: a review and author\u2019s perspective. J Cutan Aesthet Surg 7(4):189","journal-title":"J Cutan Aesthet Surg"},{"key":"2580_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/ijdvl.IJDVL_633_18","volume":"86","author":"R Sarkar","year":"2020","unstructured":"Sarkar R, Bansal A, Ailawadi P (2020) Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol 86:8\u201317","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2580_CR10","first-page":"59","volume":"46","author":"M Pistor","year":"1976","unstructured":"Pistor M (1976) What is mesotherapy? Chir Dent Fr 46:59\u201360","journal-title":"Chir Dent Fr"},{"issue":"1","key":"2580_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/0378-6323.104689","volume":"79","author":"D Konda","year":"2013","unstructured":"Konda D, Thappa DM (2013) Mesotherapy what is new? Indian J Dermatol Venereol Leprol 79(1):127\u201334","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5","key":"2580_CR12","first-page":"626","volume":"32","author":"JH Lee","year":"2006","unstructured":"Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, Park YM (2006) Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg 32(5):626\u2013631","journal-title":"Dermatol Surg"},{"issue":"3","key":"2580_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5021\/ad.2014.26.3.401","volume":"26","author":"M Cay\u0131rl\u0131","year":"2014","unstructured":"Cay\u0131rl\u0131 M, Cal\u0131\u015fkan E, A\u00e7\u0131kg\u00f6z G, Erbil AH, Ert\u00fcrk G (2014) Regression of melasma with platelet-rich plasma treatment. Ann Dermatol 26(3):401\u2013402","journal-title":"Ann Dermatol"},{"issue":"1","key":"2580_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.21608\/amj.2021.139873","volume":"50","author":"M FawzyEwaiss","year":"2021","unstructured":"FawzyEwaiss M, Mohamed El-Mohsen AE-R, Mahmoud El-Rewiny E (2021) Evaluation of intradermal tranxemic acid injection in treatment of melasma. Al-Azhar Medical J 50(1):655\u201372","journal-title":"Al-Azhar Medical J"},{"issue":"12","key":"2580_CR15","first-page":"1310","volume":"17","author":"M Serra","year":"2018","unstructured":"Serra M, Bohnert K, Narda M, Granger C, Sadick N (2018) Brightening and improvement of facial skin quality in healthy female subjects with moderate hyperpigmentation or dark spots and moderate facial aging. J Drugs Dermatology: JDD 17(12):1310\u20131315","journal-title":"J Drugs Dermatology: JDD"},{"issue":"6","key":"2580_CR16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10103-018-02698-w","volume":"34","author":"Y Jin","year":"2019","unstructured":"Jin Y, Jiang W, Yao Y, Huang H, Huang J (2019) Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study. Lasers Med Sci 34(6):1099\u20131105","journal-title":"Lasers Med Sci"},{"issue":"5","key":"2580_CR17","first-page":"502","volume":"30","author":"M Mumtaz","year":"2021","unstructured":"Mumtaz M, Chandio TH, Shahzad MK, Hanif N, Anwar S, Rafique S (2021) Comparing the efficacy of Patelet-rich Plasma (PRP) versus tranexamic Acid (4mg\/mL) as intradermal Treatments of Melasma. J Coll Physicians Surg Pak 30(5):502\u2013505","journal-title":"J Coll Physicians Surg Pak"},{"issue":"8","key":"2580_CR18","first-page":"44","volume":"14","author":"K Gharib","year":"2021","unstructured":"Gharib K, Mostafa FF, Ghonemy S (2021) Therapeutic effect of Microneedling with platelet-rich plasma versus Microneedling with Tranexamic Acid for Melasma. J Clin Aesthetic Dermatol 14(8):44\u201348","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"3","key":"2580_CR19","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1111\/ajd.13575","volume":"62","author":"AY Badran","year":"2021","unstructured":"Badran AY, Ali AU, Gomaa AS (2021) Efficacy of topical versus intradermal injection of tranexamic acid In Egyptian melasma patients: a randomised clinical trial. Australas J Dermatol 62(3):e373\u2013e379","journal-title":"Australas J Dermatol"},{"issue":"4","key":"2580_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/09546634.2018.1524821","volume":"30","author":"ER Hofny","year":"2019","unstructured":"Hofny ER, Abdel-Motaleb AA, Ghazally A, Ahmed AM, Hussein MRA (2019) Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatol Treat 30(4):396\u2013401","journal-title":"J Dermatol Treat"},{"key":"2580_CR21","doi-asserted-by":"crossref","unstructured":"Gamea MM, Kamal DA, Donia AA, Hegab DS. (2020) Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J DermatolTreat 1\u20137.","DOI":"10.1080\/09546634.2020.1781755"},{"issue":"8","key":"2580_CR22","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.12669\/pjms.38.8.6786","volume":"38","author":"C Zhang","year":"2022","unstructured":"Zhang C, Wu T, Shen N (2022) Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci 38(8):2163\u20132168","journal-title":"Pak J Med Sci"},{"issue":"7","key":"2580_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15534","volume":"35","author":"NK Patil","year":"2022","unstructured":"Patil NK, Bubna AK (2022) A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma. Dermatol Ther 35(7):e15534","journal-title":"Dermatol Ther"},{"issue":"7","key":"2580_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15499","volume":"35","author":"Y Polat","year":"2022","unstructured":"Polat Y, Sara\u00e7 G (2022) Comparison of clinical results of oral tranexamic acid and platelet rich plasma therapies in melasma treatment. Dermatol Ther 35(7):e15499","journal-title":"Dermatol Ther"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02580-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T03:41:54Z","timestamp":1689219714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02580-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2580"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02580-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}